UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

41.40 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers

January 17, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Participate in the B. Riley Healthcare Conference

January 11, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 08, 2023

From UroGen Pharma Ltd.

Via Business Wire

Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter ↗

December 07, 2023

Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of...

Via Benzinga

Recap: UroGen Pharma Q3 Earnings ↗

November 14, 2023

Via Benzinga

Preview: UroGen Pharma's Earnings ↗

November 13, 2023

Via Benzinga

The Latest Analyst Ratings for UroGen Pharma ↗

October 04, 2023

Via Benzinga

UroGen Pharma Reports Third Quarter 2023 Financial Results

November 14, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

November 13, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

November 07, 2023

From UroGen Pharma Ltd.

Via Business Wire

Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch ↗

October 09, 2023

Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.

Via Benzinga

Topics ETFs

Where UroGen Pharma Stands With Analysts ↗

July 31, 2023

Via Benzinga

UroGen Pharma Ltd. (NASDAQ: URGN) Leading the Way in Friday Trading Based on Percentage Gain

July 28, 2023

Via Investor Brand Network

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

October 03, 2023

From UroGen Pharma Ltd.

Via Business Wire

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

September 11, 2023

From Eledon Pharmaceuticals, Inc.

Via GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Ltd. (NASDAQ: URGN) Near the Top of Equities by Percentage Gain on 7/27

July 27, 2023

Via Investor Brand Network

UroGen Pharma to Present at Upcoming Investor Conferences

August 31, 2023

From UroGen Pharma Ltd.

Via Business Wire

Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

August 17, 2023

Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash...

Via Benzinga

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

August 10, 2023

From UroGen Pharma Ltd.

Via Business Wire

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 08, 2023

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

August 02, 2023

From UroGen Pharma Ltd.

Via Business Wire

$10 Trillion Added In Market Cap; 2023’s Best And Worst Through July ↗

August 01, 2023

The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023.

Via Talk Markets

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2023

From UroGen Pharma Ltd.

Via Business Wire

Why Shares of UroGen Pharma Jumped Friday ↗

July 28, 2023

The company released positive top-line results for two studies for a bladder cancer treatment.

Via The Motley Fool

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet ↗

July 28, 2023

Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...

Via Benzinga

Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 28, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why UroGen Pharma Stock Is Gaining Today? ↗

July 27, 2023

UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients...

Via Benzinga

UroGen Announces $120 Million Private Placement of Ordinary Shares

July 27, 2023

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.